Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma

Cell Research

Volumn 24, Issue 2, 2014, Pages 204-217

  Jia, Deshui ^a,b   Jing, Ying ^a,b   Zhang, Zhenfeng ^a   Liu, Li ^a   Ding, Jie ^a   Zhao, Fangyu ^a   Ge, Chao ^a   Wang, Qifeng ^c   Chen, Taoyang ^d   Yao, Ming ^a   Li, Jinjun ^a   Gu, Jianren ^a   He, Xianghuo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d QIDONG LIVER CANCER INSTITUTE   (China)

Author keywords

Copy number alterations; cortactin; hepatocellular carcinoma; migration; MPZL1

Indexed keywords

CORTACTIN; CTTN PROTEIN, HUMAN; ISOPROTEIN; MPZL1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; CHROMOSOME 1; COPY NUMBER VARIATION; DOWN REGULATION; DRUG ANTAGONISM; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 1; CORTACTIN; DNA COPY NUMBER VARIATIONS; DOWN-REGULATION; HEP G2 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, NUDE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SRC-FAMILY KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84893812364     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2013.158     Document Type: Article

References (60)

1. Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006; 25:1242-1250.
2. Yang JM, Peng ZH, Si SH, Liu WW, Luo YH, Ye ZY. KAI1 gene suppresses invasion and metastasis of hepatocellular carcinoma MHCC97-H cells in vitro and in animal models. Liver Int 2008; 28:132-139.
3. Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 2009; 49:1583-1594.
4. Lee TK, Poon RT, Yuen AP et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006; 12:5369-5376.
5. Yao J, Liang L, Huang S et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010; 51:846-856.
6. Ding J, Huang S, Wu S et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 2010; 12:390-399.
7. Ying Q, Liang L, Guo W et al. Hypoxia-inducible microRNA- 210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein in hepatocellular carcinoma. Hepatology 2011; 54:2064-2075.
8. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29:4989-5005.
9. Shlien A, Malkin D. Copy number variations and cancer susceptibility. Curr Opin Oncol 2010; 22:55-63.
10. Hahn WC, Dunn IF, Kim SY et al. Integrative genomic approaches to understanding cancer. Biochim Biophys Acta 2009; 1790:478-484.
11. Firestein R, Bass AJ, Kim SY et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008; 455:547-551.
12. Jia D, Wei L, Guo W et al. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology 2011; 54:1227-1236.
13. Sawey ET, Chanrion M, Cai C et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011; 19:347-358.
14. Lau SH, Guan XY. Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin 2005; 26:659-665.
15. Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin 2010; 31:1165-1171.
16. Ma NF, Hu L, Fung JM et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 2008; 47:503-510.
17. Zannettino AC, Roubelakis M, Welldon KJ et al. Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: Identification, molecular cloning and effects on cell migration. Biochem J 2003; 370:537-549.
18. Roubelakis MG, Martin-Rendon E, Tsaknakis G, Stavropoulos A, Watt SM. The murine ortholog of the SHP-2 binding molecule, PZR accelerates cell migration on fibronectin and is expressed in early embryo formation. J Cell Biochem 2007; 102:955-969.
19. Eminaga S, Bennett AM. Noonan syndrome-associated SHP- 2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem 2008; 283:15328-15338.
20. Kusano K, Thomas TN, Fujiwara K. Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells. Endothelium 2008; 15:127-136.
21. Roessler S, Jia HL, Budhu A et al. A unique metastasis gene signature enables prediction of tumor relapse in earlystage hepatocellular carcinoma patients. Cancer Res 2010; 70:10202-10212.
22. Chen X, Cheung ST, So S et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13:1929-1939.
23. Cui JF, Liu YK, Zhang LJ et al. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 2006; 6:5953-5961.
24. Genda T, Sakamoto M, Ichida T et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999; 30:1027-1036.
25. Anderson K, Potter A, Baban D, Davies KE. Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology. Brain 2003; 126:2052-2064.
26. Huang GJ, Yang CM, Chang YS et al. Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways. J Agric Food Chem 2010; 58:9468-9475.
27. Kang S, Elf S, Lythgoe K et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest 2010; 120:1165-1177.
28. von Sengbusch A, Gassmann P, Fisch KM, Enns A, Nicolson GL, Haier J. Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids. Am J Pathol 2005; 166:585-596.
29. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22:337-358.
30. Buday L, Downward J. Roles of cortactin in tumor pathogenesis. Biochim Biophys Acta 2007; 1775:263-273.
31. Yamada S, Yanamoto S, Kawasaki G, Mizuno A, Nemoto TK. Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma. Pathol Oncol Res 2010; 16:523-531.
32. Li Y, Tondravi M, Liu J et al. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001; 61:6906-6911.
33. Kanner SB, Reynolds AB, Vines RR, Parsons JT. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A 1990; 87:3328-3332.
34. Zhao R, Guerrah A, Tang H, Zhao ZJ. Cell surface glycoprotein PZR is a major mediator of concanavalin A-induced cell signaling. J Biol Chem 2002; 277:7882-7888.
35. Walter AO, Peng ZY, Cartwright CA. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene 1999; 18:1911-1920.
36. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. Role of c-Src tyrosine kinase in G proteincoupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 1996; 271:19443-19450.
37. Shadeo A, Lam WL. Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 2006; 8:R9.
38. Partheen K, Levan K, Osterberg L, Helou K, Horvath G. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage. Genes Chromosomes Cancer 2004; 40:342-348.
39. Saramaki OR, Porkka KP, Vessella RL, Visakorpi T. Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer 2006; 119:1322-1329.
40. Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450:893-898.
41. Zhao ZJ, Zhao R. Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2. J Biol Chem 1998; 273:29367-29372.
42. Sanchez-Carbayo M. Antibody arrays: Technical considerations and clinical applications in cancer. Clin Chem 2006; 52:1651-1659.
43. Roberts CJ, Nelson B, Marton MJ et al. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. Science 2000; 287:873-880.
44. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009; 284:5731-5741.
45. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131:1190-1203.
46. Zhao R, Fu X, Teng L, Li Q, Zhao ZJ. Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology domains. J Biol Chem 2003; 278:42893-42898.
47. Chen L, Wang ZW, Zhu JW, Zhan X. Roles of cortactin, an actin polymerization mediator, in cell endocytosis. Acta Biochim Biophys Sin (Shanghai) 2006; 38:95-103.
48. Sung BH, Zhu X, Kaverina I, Weaver AM. Cortactin controls cell motility and lamellipodial dynamics by regulating ECM secretion. Curr Biol 2011; 21:1460-1469.
49. Eckert MA, Lwin TM, Chang AT et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011; 19:372-386.
50. Chuma M, Sakamoto M, Yasuda J et al. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol 2004; 41:629-636.
51. Weaver AM. Cortactin in tumor invasiveness. Cancer Lett 2008; 265:157-166.
52. Echeverri CJ, Perrimon N. High-throughput RNAi screening in cultured cells: A user's guide. Nat Rev Genet 2006; 7:373-384.
53. Whitehurst AW, Bodemann BO, Cardenas J et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446:815-819.
54. Ren G, Helwani FM, Verma S, McLachlan RW, Weed SA, Yap AS. Cortactin is a functional target of E-cadherin-activated Src family kinases in MCF7 epithelial monolayers. J Biol Chem 2009; 284:18913-18922.
55. Jia D, Yan M, Wang X et al. Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 2010; 10:364.
56. Perek B, Malinska A, Stefaniak S et al. Predictive factors of late venous aortocoronary graft failure: Ultrastructural studies. PLoS One 2013; 8:e70628.
57. Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Hosoda Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989; 13:1064-1067.
58. Pirisi M, Leutner M, Pinato DJ et al. Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med 2010; 134:1818-1822.
59. Zhao X, Li C, Paez JG et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64:3060-3071.
60. Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64:4442-4452.